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COMMENTARY
Under one roof: identification, 
evaluation, and treatment of chronic hepatitis C 
in addiction care
Stephen A. Martin1,2,3*, Jordon Bosse4, Amanda Wilson3, Phyllis Losikoff5,6 and Lisa Chiodo3,4
Abstract 
For over a decade, the vast majority of new hepatitis C virus (HCV) infections have been among young people who 
inject drugs (PWID). Well-characterized gaps in chronic HCV diagnosis, evaluation, and treatment have resulted in 
fewer than 5% of PWID receiving HCV treatment. While interferon-based treatment may have intentionally been fore-
gone during part of this time in anticipation of improved oral therapies, the overall pattern points to deficiencies and 
treatment exclusions in the health care system. Treatment for HCV with all-oral, highly effective direct-acting antiviral 
medication for 12 weeks or less is now the standard of care, putting renewed focus on effective delivery of care. We 
describe here both the need for and process of chronic HCV care under the roof of addiction medicine.
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Background
Two profound changes in chronic hepatitis C virus 
(HCV) infection have occurred over the past decade. 
The first is the availability of medications that allow an 
all-oral highly effective cure. These direct-acting antiviral 
(DAA) agents have few adverse effects and enable treat-
ment completion in as little as 8–12 weeks, with success 
rates exceeding 90% [1]. They are sorely needed given 
that HCV is now the leading cause of infectious death in 
the United States [2] and the most common cause of liver 
transplant [3].
The second change is the development of a bimodal 
chronic HCV demographic, with American Baby Boom-
ers joined by young people who inject drugs (PWID). 
Among new acute HCV cases in 2014, more than two-
thirds (68.2%) reported injection drug use [4]. HCV inci-
dence had been in decline until early 2000s, a success 
enabled by identification of the virus in 1989. Subsequent 
blood product screening prior to transfusion, begun in 
1990, virtually eliminated this mode of HCV transmission 
by 1992. Needle exchange efforts and a decrease in injec-
tion drug use further helped HCV incidence to decline 
to below 1 per 100,000 by the early 2000s. Between 2010 
and 2015 this trend reversed, with acute HCV infections 
rising nearly threefold—a figure likely underestimated by 
a factor of 15 [2, 5].
Patients who are not able to obtain HCV treatment risk 
transmitting the virus to others, which in turn, leads to 
higher incidence of disease and subsequent illness. Dou-
bling the number of patients treated each year, however, 
could decrease HCV prevalence to fewer than 100,000 
cases by 2030 [6]. This approach, similar to that pursued 
for HIV, has been termed treatment (or cure) as preven-
tion (CasP) [7–9]. Given the impact of HCV on individu-
als who are infected and their families, the health care 
system, and larger society, minimizing barriers and maxi-
mizing access to more easily tolerated evidence-based 
treatment for younger persons who inject drugs is imper-
ative. Yet PWID are often relatively isolated, even stigma-
tized, by standard health care [10].
The HCV treatment cascade (see Table  1) describes 
the clinical course, from initially evaluating HCV risk 
to finally achieving sustained virologic response (SVR). 
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There are substantial impediments at each stage [11, 12]. 
Two recent cohort studies examined this younger popu-
lation—people with opioid use disorder (OUD) in med-
ication-assisted treatment who have chronic HCV. Both 
found < 3% of patients initiated HCV treatment [13, 14].
Many barriers to treatment can be removed through 
treatment at a trusted place where HCV testing occurs. 
This would allow for immediate counseling and treat-
ment evaluation after a positive result [15]. Given the 
high risk for HCV with the use of injection drugs, sites 
for outpatient treatment of OUD are a logical starting 
point to provide this range of HCV services. In 2017, this 
approach was strongly supported by the American Soci-
ety of Addiction Medicine, which stated that “integra-
tion of service delivery, addressing the unique needs of 
addiction patients including HCV treatment, is strongly 
encouraged” [16]. HCV treatment in settings of OUD 
care is successful in Australia [17], Switzerland [18], and 
Italy [19]. Recently this success was repeated in Con-
necticut in a primary care setting embedded in an opioid 
treatment center [20].
HCV and medication assisted treatment care 
integration
Over the past year, we have been learning from the pilot 
provision of HCV treatment as part of meeting our 
patients’ health needs—independent of primary care 
and eliminating multiple steps of the usual HCV treat-
ment cascade (Table 1). CleanSlate Addiction Treatment 
Centers offers dedicated treatment for opioid and alcohol 
use disorders in eight states, with clinicians that include 
social workers, advanced practice clinicians, and physi-
cians. Patients in treatment for OUD at CleanSlate have 
a median age of 36  years old, with 26% under the age 
of 30 and 64% under the age of 40. As such, they repre-
sent the demographic profile of the younger person with 
OUD and an elevated risk of chronic HCV infection. As 
the treatment cascade makes clear, caring for a group of 
patients with a high burden of chronic HCV does not 
inevitably lead to its cure; the combination of an effec-
tive treatment strategy together with longitudinal care is 
especially helpful. The average length of treatment in our 
buprenorphine program is over one year (SD = 1.3, range 
0.2–5.5). This timeframe is well beyond the 12 weeks of 
HCV treatment needed and allows providers more time 
with their patients to develop therapeutic relationships. 
Additional time spent with patients allows providers to 
assess patients’ stability and motivation for treatment and 
provide education, which, in the context of the therapeu-
tic relationship, can maximize adherence to treatment.
All patients who initiate substance use disorder treat-
ment at CleanSlate are screened for blood-borne patho-
gens: Hepatitis B (HBV), Human Immunodeficiency 
Virus (HIV), and HCV testing that reflexes to a HCV 
viral count for all HCV antibody-positive specimens. By 
screening all patients we have found a 25–30% preva-
lence of positive HCV antibody; 75% of these patients 
with positive HCV antibody are subsequently found to 
have chronic HCV. All addiction providers are trained in 
HCV pre- and post-test counseling, including educating 
patients about DAA. Standard of care has been to refer 
all HCV infected patients to community providers for 
further evaluation and treatment [21].
In 2016, we began a pilot program in one of our clinics 
offering treatment for chronic HCV infection together 
with addiction treatment. Results of our pilot found 
that co-location of HCV treatment in our addiction 
clinic reduces the care cascade attrition found in PWID 
populations. In our pilot site sample, of the approxi-
mately 740 patients who were screened, 167 (22.5%) 
patients were found to have chronic HCV. All are in the 
process of being offered treatment. As of September 1, 
2017, 72 (43%) entered DAA treatment. Among those 
who entered treatment, 72% received HCV treatment at 
CleanSlate and 28% chose to receive care via commu-
nity treatment. Of the patients receiving care at our site 
Table 1 Mechanisms to address gaps in treatment cascade [16, 23]
Cascade step Outpatient addiction treatment site advantages Cascade step eliminated
1. Patients are diagnosed and aware of their infection Standardized screening of all patients and counseling with 
results
2. Linkage to care (Access to outpatient care) HCV care remains at the site ✓
3. Confirmatory testing for HCV RNA Standardized reflex testing ✓
4. Liver disease evaluation, including liver biopsy (Note: Liver 
biopsy is not required for all patients)
Blood-based biomarker testing, a recommended alternative 
to liver biopsy, can be readily performed on site
✓
5. Prescribed HCV treatment Prescribed on site with coordination from specialty pharma-
cies
✓
6. Achieved a sustained virologic response (SVR), also 
referred to as being cured
SVR testing done on site ✓
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who have reached 12  weeks after treatment completion 
(N  =  48), 4 have been lost to follow-up and 2 did not 
complete treatment. One patient had a treatment failure 
at 12  weeks post-treatment. Our on-site rate of cure is 
85% (41 of 48) using intention-to-treat analysis and 98% 
(41 of 42) among those for whom we have SVR data. In a 
similar CleanSlate without co-located care site, only 10% 
entered DAA care in the community.
Three HCV treatment model strategies have been criti-
cal for success; each lends itself to scaling and sustain-
ability. First, we have in-house expertise of an infectious 
disease specialist with interest in both addiction care and 
HCV. This expert mentors advanced practice clinicians 
to independently treat HCV and also directs clinical 
care for patients with different severities of cirrhosis and 
associated complications. This expertise can be remotely 
offered to other sites. Though many sites for OUD treat-
ment do not have infectious disease specialists, our sense 
is that partnerships with them allow a novel, effective 
way to meet the needs of a high-risk population and, by 
extension, contribute to cure as prevention.
Second, just as our clinical experience with OUD 
registries lent itself to HCV treatment, we have repur-
posed staff expertise with prior authorizations, medica-
tion management, and treatment adherence. Laboratory 
staff have been especially helpful in facilitating both our 
screening and treatment protocols.
Third, we are using the model of a learning, capacity-
building organization, with clinicians (advanced practice 
clinicians and physicians) taking part in an HCV Project 
ECHO and developing new skills in HCV care [22]. Over 
the course of several months of ECHO participation—
including presenting de-identified cases and listening to 
others’ cases—we were able to develop advanced prac-
tice clinician skills to provide treatment independently. 
The ECHO has also been a place where we can share and 
learn about newer treatments and approaches in this rap-
idly-developing field.
Conclusion
People with chronic HCV currently face fragmented care 
provision, including diagnosis and cure of chronic HCV. 
Addiction treatment programs are uniquely situated 
to either use their existing program infrastructures or 
expand current programming to increase access to HCV 
care and treatment. By recognizing the unique, trusted, 
ongoing clinical role we play in many patients’ lives, we 
can help their health beyond addiction.
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We describe in this manuscript a model of care in place at CleanSlate Addic-
tion Treatment Centers. It is not intrinsic to our organization, and we make the 
case that it can—and should—be implemented at many other sites of care for 
substance use disorders.
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